ITM Isotopen Technologien München AG

ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. ITM has established the GMP manufacturing and a robust global supply network for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

ITM at a glance:

Field of Activity
Precision Medicine, Precision Oncology, Targeted Radionuclide Therapy / PRRT

1) Development of targeted radiopharmaceuticals for cancer treatment
2) Therapeutic & diagnostic radionuclides
3) Equipment for Radiolabeling & Quality Control:
iQS-Theranostics Synthesizer, iQS
® Ga-68 Fluidic Labeling ­Module, Consumables (Reagent Sets, Cassettes), Quality Control Solution (radio-HPLC)
4) GMP Radiolabeling Service

Our lead candidate Solucin® (n.c.a. 177Lu-Edotreotide) is currently under investigation in the phase III clinical trial COMPETE. COMPETE is an international pivotal multi-center phase III clinical trial evaluating the efficacy and safety of n.c.a. 177Lu-Edotreotide (Solucin®) compared to the standard therapy with Everolimus in patients with inoperable, progressive, somatostatin-receptor positive neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET).

Unique Selling Point ITM is developing and producing medical radionuclides and radiopharmaceuticals of extraordinary quality and highest standard. ITM has established a global sales network and delivers radionuclides to more than 250 sites worldwide. We collaborate with over 30 distribution partners in more than 46 countries.
Membership in networks/associations

BioM Biotech Cluster Development GmbH, BIO Deutschland e.V.,
ENETS European Neuroendocrine Tumor Society,
The Carcinoid Cancer Foundation, Inc. (Patient Organization)

Date of Incorporation/
Number of Employees



Address Lichtenbergstr. 1
85748 Garching
Telephone +49 89 329 8986-600
Web Address


Social Media

LinkedIn | Twitter | Facebook

Artikel über ITM Isotopen Technologien München AG:

21.03.2016 20 Mio. EUR-Finanzierung für Theranostic-Firma ITM